Evidence map›Paper›PMID 30277654›Full record

ArticleNeuropsychopharmacology reports2018

Gamma-aminobutyric acid transaminase genetic polymorphism is a candidate locus for responsiveness to opioid analgesics in patients with cancer pain: An exploratory study.

Yaeko Yokoshima, Masahiko Sumitani, Daisuke Nishizawa, Makoto Nagashima, Kazutaka Ikeda, Ryoji Kato, Jun Hozumi, Hiroaki Abe, Kenji Azuma, Rikuhei Tsuchida and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yaeko YokoshimaDepartment of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
Masahiko SumitaniDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.ORCID 0000-0002-3662-8217
Daisuke NishizawaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Makoto NagashimaDepartment of Surgery, Toho University Medical Center, Sakura Hospital, Chiba, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID 0000-0001-8342-0278
Ryoji KatoDepartment of Surgery, Toho University Medical Center, Sakura Hospital, Chiba, Japan.
Jun HozumiDepartment of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
Hiroaki AbeDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Kenji AzumaDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Rikuhei TsuchidaDepartment of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
Yoshitsugu YamadaDepartment of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
Japanese TR-Cancer Pain Research Group
University of Tokyo Hospital · JPToho University · JPTokyo Metropolitan Institute of Medical Science · JP

Funding

Ministry of Health, Labour, and Welfare Science Research Grant H21-Cancer-011Ministry of Health, Labour, and Welfare Science Research Grant H26-Cancer-060
6 · The paper itself

Abstract

aimCancer pain impairs not only physical functions but also social functions and roles. Consequently, the overall health-related quality of life of patients with cancer pain deteriorates. Opioid analgesics are recommended for treating moderate to strong cancer pain. Advances in human genome research have fueled a growing interest to understand individual differences in responsiveness to opioid analgesics. This study aimed to explore and identify novel loci for genes predisposing an individual to opioid analgesic responsiveness.

methodsA total of 71 cancer patients rated their pain on an 11-point numerical rating scale twice before and after increasing opioid analgesics. A genomewide association study focusing on single nucleotide polymorphisms (SNPs) was conducted to associate pain decrease with increased dosage of opioid analgesics based on weight (ie, responsiveness to opioid analgesics). A genomewide significance (P < 5E-8) was set for multiplicity of analyses to control for false positives.

resultsTwo SNPs passed the genomewide threshold for significance. One exonic SNP (rs1641025) was located in the ABAT [4-aminobutyrate aminotransaminase (GABA transaminase)] gene on chromosome 16. The other SNP (rs12494691) was located on chromosome 3, which was not associated with any known genes. These SNPs were not associated with opioid-related adverse effects.

conclusionsOur results preliminarily suggest that both SNPs might be potential candidate loci for responsiveness to opioid analgesics, and GABA transaminase might be a possible target for developing adjuvant pharmacotherapy with opioid analgesics in adjuvant pharmacotherapy. Our results should be validated in a large-scale study with a larger sample size.

Indexed as

Polymorphism, Single Nucleotide4-Aminobutyrate TransaminaseAdultAgedAnalgesics, OpioidCancer PainDrug ResistanceFemaleHumansMaleMiddle Aged4-Aminobutyrate TransaminaseAnalgesics, Opioidgenetics: humanpain: basic/clinicalpharmacogenetics: basic/clinicalresponsiveness to opioid analgesics

Identifiers

PMID30277654
PMCPMC7292329
OpenAlexW2891193667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.